Skip to main content
Figure 2 | Journal of Nanobiotechnology

Figure 2

From: On-chip constructive cell-network study (II): on-chip quasi-in vivo cardiac toxicity assay for ventricular tachycardia/fibrillation measurement using ring-shaped closed circuit microelectrode with lined-up cardiomyocyte cell network

Figure 2

Abnormal beating and fibrillation caused by arrhythmia compound (Astemizole) in a circuit-type mouse embryonic cardiomyocyte network. (a) Procedure of compound application. (b) time course FP (quasi-in vivo ECG of ST interval) profiles after addition of 1 μM Astemizole, (c) Astemizole concentration dependence of FP waveform change. (d)-(f) Astemizole concentration dependence of FP waveform change in beating frequency (d), ST (e), and short-term variability (STV) of ST (f) in three different ring shape electrodes of 1 mm in diameter. *: p < 0.05, **: p < 0.01, ***: P < 0.005, compareed to control in paired t-test.

Back to article page